FDA Panel: Avandia Should Remain on Market

A panel of outside experts recommended to the FDA on Monday afternoon that the diabetes drug Avandia should be kept on the market, despite concern over its heart risks. Though 20 of the 23 panelists agreed that use of the drug increased heart risks for those with diabetes, 22 out of 23 said that the balance between the drugs benefits and risks supported its continued use in the United States. But nearly all the panelists agreed that the drug's warning label should be strengthened to reflect...Full Story
Commenting on this article is closed.